Xingxing Zang

Dr. XingXing Zang holds the Louis Goldstein Swan Chair in Cancer Research and is a Professor of Immunology, Oncology, Medicine, and Urology at the Albert Einstein College of Medicine in New York. Dr. Zang’s research has focused on new immune checkpoint pathways, from basic discoveries to translational clinical trials. He discovered the B7 molecules B7x and HHLA2 as well as HHLA2’s functionally opposed receptors, TMIGD2 and KIR3DL3. Dr. Zang has also demonstrated new mechanisms and structures of other immune checkpoints, such as B7-H3, ICOS, Tim-3, KIR2DL5/PVR, PD-L1/PD-1, and BTNL2, and has developed new immunotherapies. Dr. Zang is the scientific founder of NextPoint Therapeutics and has served on scientific advisory boards of several biopharmaceutical companies.

Dr. Zang received a MMed from Shanghai Jiao Tong University School of Medicine in China, a PhD from the University of Edinburgh, Scotland, in the laboratory of Rick M. Maizels, and had postdoctoral training with James P. Allison at the University of California at Berkeley and at Memorial Sloan Kettering Cancer Center.